



Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: AMRN

| | |
|---------------|----------------------------|
| Last Trade: | 3.36 |
| Trade Time: | 4:00 PM ET Nov 22, 2017 |
| Change: | 0.04 (+1.205%) |
| Day Range | 3.29 - 3.40 |
| 52-Week Range | 2.81 - 4.47 |
| Volume | 842,371 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 14, 2017
[Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk](#)
- Nov 13, 2017
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease](#)
- Nov 13, 2017
[Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs](#)
- Nov 7, 2017
[Amarin to Present at the Jefferies London Healthcare Conference](#)
- Nov 1, 2017
[Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017
[Annual Report \(10-K\)](#)
- Apr 21, 2017
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017
[Quarterly Report \(10-Q\)](#)
- May 3, 2017
[Quarterly Report \(10-Q\)](#)